ITASCA,
Ill., Jan. 7, 2025 /PRNewswire/ -- Lakeside
Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a
U.S.-based cross-border supply chain solution provider with a
unique focus on the Asia-Pacific
market today announced that Hupan Pharmaceutical has entered into a
strategic distribution agreement with Sichuan Huiyu Pharmaceutical
Co., Ltd. ("Huiyu Pharmaceutical").
Huiyu Pharmaceutical is a leading innovator in oncology and
immune-related therapies, listed on the Shanghai Stock Exchange
(688553.SS). Huiyu Pharmaceutical is renowned for its robust
R&D capabilities, cutting-edge manufacturing process, and a
strong commitment to address critical healthcare needs
worldwide.
Under the agreement, Hupan Pharmaceutical will distribute Huiyu
Pharmaceutical's highly regarded oncology and immunotherapy drugs
to hospitals and healthcare institutions to domestic and global
markets. Huiyu Pharmaceutical's flagship
product, Pemetrexed Disodium for Injection, has
received regulatory approvals in major markets, including
China, the UK, Germany, and Finland, and is widely recognized for its
efficacy in treating non-small cell lung cancer (NSCLC) and
malignant pleural mesothelioma.
Lan Su, COO of Lakeside Holding
Limited, commented, "Our strategic partnership with Huiyu
Pharmaceutical allows us to help expand the reach of their
innovative oncology solutions and deliver life-saving treatments to
broader markets. We are proud to use our healthcare distribution
capabilities to reach patients domestically and abroad."
Zhao Ding, President at Huiyu
Pharmaceutical, commented, "We look forward to partnering with
Hupan Pharmaceutical to provide reliable and efficient distribution
channels for our therapies, so they can reach patients when needed
and improve patient outcomes."
About Lakeside Holding Limited
Lakeside Holding Limited is a U.S.-based cross-border supply
chain solution provider with a unique focus on the Asia-Pacific market. Through two specialized
subsidiaries—American Bear Logistics and Hupan Pharmaceutical
(Hubei) Co., Ltd.—Lakeside
delivers tailored logistics solutions spanning general and
specialized sectors.
American Bear Logistics, with strategic hubs in Chicago, Dallas, Los
Angeles, and New York,
offers customized cross-border ocean and airfreight solutions,
connecting Asia-based logistics
service companies and e-commerce platforms with the U.S.
market.
Lakeside recently acquired Hupan Pharmaceutical (Hubei) Co., Ltd., expanding its service scope
and enhancing its pharmaceutical logistics and distribution
capabilities within China. This
strategic move underscores Lakeside's commitment to advancing
integrated cross-border logistics solutions.
For more information, please
visit https://lakeside-holding.com.
Safe Harbor Statement
This press release contains forward-looking statements that
reflect our current expectations and views of future events. Known
and unknown risks, uncertainties and other factors, including those
listed under "Risk Factors," may cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. You can
identify some of these forward-looking statements by words or
phrases such as "may," "will," "expect," "anticipate," "aim,"
"estimate," "intend," "plan," "believe," "is/are likely to,"
"potential," "continue" or other similar expressions. We have based
these forward-looking statements largely on our current
expectations and projections about future events that we believe
may affect our financial condition, results of operations, business
strategy and financial needs. These forward-looking statements
involve various risks and uncertainties. Except as required by law,
we undertake no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, after the date on which the statements
are made or to reflect the occurrence of unanticipated events. We
qualify all of our forward-looking statements by these cautionary
statements.
Investor Relations Contact:
Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com
View original
content:https://www.prnewswire.com/news-releases/lakeside-partners-with-huiyu-pharmaceutical-to-revolutionize-oncology-drug-distribution-302343673.html
SOURCE Lakeside Holding Limited
